Acute (single dose, opioid-naive, BZD-naive user, 0.5-1 mg PO)

• Onset 30-60 minutes oral; peak effect 1-2 hours. Sublingual (Niravam) ~15-30 min faster.
• Anxiolytic — the dissociative-quality calm characteristic of all clinical benzodiazepines. "The anxiety just stops mattering" rather than the absence of anxious thoughts. Alprazolam specifically tends to feel stronger than equivalent doses of clonazepam or diazepam due to the rapid onset.
• Mildly euphoric — the rapid rise produces a subjective "rush" that drives most of the abuse liability. More pronounced than oral diazepam (slower absorption); comparable to IV diazepam or sublingual lorazepam in subjective intensity.
• Sedating — drowsiness, slowed reaction time, ataxia at higher doses (>1 mg in BZD-naive users).
• Anterograde amnesia at higher doses — the "Xanax bar blackout" phenomenon. Fragmented or absent memory of events for hours after dosing. Documented in clinical trials and forensic literature.
• Disinhibition — paradoxical aggression, impulsivity, or sexual disinhibition occur in 1-10% of users; can be severe (Bond et al., Psychopharmacology 1995 documented this in alprazolam specifically).
• Muscle relaxation — pleasant for some, unsteady for others.

Chronic (after 2-6 weeks of daily or near-daily use)

• Tolerance — "I need 1 mg now where 0.5 was working." Sedation tolerance develops faster than anxiolytic tolerance, but both develop.
• Inter-dose anxiety — anxiety rises 4-8 hours after the prior dose, often worse than baseline. This is the dependence loop.
• Cognitive flattening — "brain fog," difficulty learning new material, slower processing. Often unnoticed by user, obvious on neuropsych testing.
• Emotional blunting — calmer, less able to feel pleasure (anhedonia signal).
• Sleep architecture distortion — REM and slow-wave sleep both suppressed; total sleep time may be longer but objective quality is worse.
• Dose creep — typical trajectory is 0.5 mg PRN → 0.5 mg BID → 0.5-1 mg TID → escalation requested at 6-12 month follow-up.

Withdrawal (after weeks-months of daily use, abrupt or rapid cessation)

• Acute (days 1-14): rebound anxiety often worse than baseline, insomnia, tremor, sweating, tachycardia, headache, photophobia, hyperacusis, depersonalization, akathisia, perceptual disturbances. Seizures are possible — and the risk is highest with alprazolam among common benzodiazepines because of the short half-life + high potency combination. Seizures can be fatal. Delirium possible in heavy / long-duration users (similar phenomenology to alcohol DTs). Onset is faster than longer-acting benzodiazepines: alprazolam withdrawal symptoms typically begin 12-24 hours after the last dose vs 24-72 hours for clonazepam or diazepam.
• Sub-acute (weeks 2-8): persistent anxiety, insomnia, mood lability, cognitive symptoms, GI distress, paraesthesia.
• Protracted (BIND, months 2-18+): intermittent waves of the above. ~10-15% of long-term users per patient-survey data (Huff et al., 2023 Therapeutic Advances in Psychopharmacology; PLOS One 2024 scoping review). Resolution slow, sometimes incomplete.

• Tolerance buildup: fast. Sedation tolerance days-weeks, anxiolytic tolerance weeks-months, anticonvulsant tolerance months. Cognitive impairment shows little tolerance.
• Recommended cycle: there isn't one that's safe long-term. PRN-only use with self-imposed limits (<2× per week, <4 doses per month) is the maximum cycling discipline most users sustain, and even that drifts upward over months.
• Reset protocol: there is no "reset" — there is only taper. Ashton-Manual taper specifically for alprazolam: substitute equivalent diazepam (0.5 mg alprazolam ≈ 10 mg diazepam by Ashton's table) before starting reduction, then reduce by ~10% of current dose every 1-2 weeks, slower in the last 25%, total taper duration 6-18 months for chronic users. The diazepam substitution step is particularly important for alprazolam because the short half-life makes direct alprazolam taper unstable — patients oscillate through inter-dose withdrawal repeatedly. Cold-turkey from chronic high-dose alprazolam is medically contraindicated (seizure risk).

Synergistic with (DANGEROUSLY)

• Opioids (fentanyl, oxycodone, hydrocodone, heroin, methadone, buprenorphine) — respiratory depression, primary overdose-death mechanism. FDA Boxed Warning since 2016. Methadone + alprazolam specifically has historically been documented in roughly half of methadone-program overdose deaths in some cohorts. Avoid co-prescribing.
• Alcohol — additive CNS depression and respiratory depression. Common cause of accidental death. Alcohol also induces CYP3A4 in chronic use, complicating PK.
• Z-drugs (zolpidem, zopiclone, eszopiclone) — same GABA-A α1 site, additive sedation and respiratory depression. Do not stack.
• Barbiturates — additive at GABA-A; high lethality in combination.
• Other CNS depressants — first-generation antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants, antipsychotics, gabapentinoids (gabapentin, pregabalin), GABA-B agonists (baclofen, phenibut, GHB/GBL) — additive sedation and cognitive impairment; in some combinations (alprazolam + gabapentin + opioid is a particularly common ED-overdose triad) lethality risk is substantial.

Avoid stacking with (overlapping mechanism / wasteful)

• L-theanine — not dangerous but redundant; theanine is a much milder GABAergic/anxiolytic and the alprazolam swamps any theanine effect. Theanine is the better daily anxiolytic precisely because it has none of the dependence/withdrawal/cognitive-impairment liability.
• Magnesium glycinate — same logic; magnesium is the better daily lever for GABAergic tone without addiction.
• Other benzodiazepines — redundant + cumulative risk. If switching benzodiazepines, do it as part of a taper (typically into diazepam for taper purposes), not as a stack.
• Phenibut — phenibut is a GABA-B + α2δ calcium channel ligand with its own severe withdrawal syndrome; stacking compounds dependence pharmacology.

CYP3A4 — the major axis

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nefazodone, fluvoxamine, large grapefruit-juice intake): substantially raise alprazolam levels and extend half-life. Avoid co-administration; if unavoidable, use lower alprazolam dose under prescriber.
• Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil, ciprofloxacin): meaningful alprazolam level increase. Dose-adjust.
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John's wort, some HIV NNRTIs): reduce alprazolam levels.
• Fluoxetine and fluvoxamine specifically: SSRI + alprazolam interaction is clinically common. Fluvoxamine is a strong 3A4 inhibitor; fluoxetine is moderate. Both raise alprazolam levels.
• Oral contraceptives (ethinyl estradiol): inhibit CYP3A4 weakly; alprazolam levels can rise modestly.

Specific high-mortality combinations

• Alprazolam + opioid (especially fentanyl, methadone, oxycodone): respiratory depression; ~70% of US benzodiazepine-involved overdose deaths in 2023 also involved an opioid (CDC data). Specific to alprazolam due to prescription volume and abuse liability.
• Alprazolam + alcohol: additive depression. Common accidental-death pattern.
• Alprazolam + Z-drug (zolpidem, eszopiclone): additive sedation; documented overdose pattern.
• Alprazolam + counterfeit pill of unknown content: this is the 2020s pattern — a user takes "Xanax" expecting alprazolam pharmacology and receives a fentanyl-equivalent pressed pill. The supply-chain interaction is the dominant practical concern.

CYP and pharmacogenomic

• CYP3A4*22 (reduced enzyme activity): higher alprazolam exposure.
• CYP3A5*3 (most common variant in non-African ancestry): minor effect on alprazolam.
• CYP3A4*1B: minor effect.
• The clinical impact of these polymorphisms on alprazolam is generally modest compared to enzyme inhibitor / inducer co-administration.

Other notable

• Digoxin: alprazolam can raise digoxin levels in elderly patients (specific clinical interaction).
• TCAs: pharmacokinetic interactions modest; pharmacodynamic (additive sedation, anticholinergic) significant.
• Antifungals (azoles): strong 3A4 inhibition; substantial alprazolam level rise.

• CYP3A4 polymorphisms (CYP3A4*22 reduces activity) — affect alprazolam exposure modestly.
• CYP3A5 polymorphisms — minor alprazolam effect.
• GABA-A receptor polymorphisms (GABRA1, GABRA2, GABRB3) — research-stage; weak signal for variability in benzodiazepine response, sedation, and possibly addiction liability.
• For the user's 23andMe data (results pending June 2026): no clinically actionable alprazolam-specific flags expected. CYP3A4*22 if present would suggest reduced metabolism / longer half-life / higher exposure at given dose — relevant only if alprazolam ever became indicated.

For the user: not sourcing this, full stop. Even for a hypothetical legitimate one-off PRN use case, the path is "talk to a prescriber for a genuine medical reason" not "source from gray market." The fentanyl-contamination risk in the counterfeit supply makes informal sourcing a Russian-roulette pattern with nontrivial mortality probability, not a tolerable risk-reward tradeoff for any benefit alprazolam offers vs cleaner alternatives (propranolol, buspirone, theanine, CBT, exercise).

For chronic users (which the user is not and will not be):

• Baseline (before starting): anxiety scale (HAM-A or GAD-7), cognitive battery (CNS Vital Signs, RAVLT, n-back), sleep architecture (Oura/Whoop deep + REM baseline), CMP (liver/kidney), CBC.
• During use: subjective anxiety (GAD-7 quarterly), sleep quality, cognitive symptoms, dose creep documentation, PRN use frequency log (if PRN), inter-dose anxiety log (the dependence-formation early-warning signal).
• Post-cycle / post-taper: cognitive battery repeat at 1 month, 6 months, 12 months post-taper to characterize recovery and detect BIND.
• Drug-supply chain trust verification: if for any reason a prescription is filled outside a verified US pharmacy chain, do not use the pills until verified — fentanyl test strips reduce but do not eliminate counterfeit-pill risk.

For PRN single-dose use under prescriber: none routine beyond the medical event documentation.